Valence 로고
인기
로그인
Loading data for MGX — first visit, this takes a few seconds.

관심목록에 추가

Metagenomi Therapeutics I...

NasdaqGS: MGX · 실시간 가격 · USD
1.21
-0.01 (-0.82%)
종가 기준: Aug 18, 2026, 8:00 PM

Metagenomi Therapeutics Inc. (MGX) Stock Price, Analysis & Data

-0.82%

데이터 없음

매수호가n/a
시가총액45.71M
매출 (ttm)13.56M
순이익 (ttm)-93.46M
베타0.67
EPS (ttm)-2.49
P/E (ttm)n/a
선행 P/E-0.66
P/B (ttm)0.41
P/S (ttm)3.37
Earnings DateAug 13, 2025
매도호가n/a
거래량66,485
평균 거래량 (20일)165,904
시가1.23
전일 종가1.22
일중 범위1.20 - 1.24
52주 범위1.13 - 3.95
애널리스트n/a
목표주가n/a
배당n/a
배당락일n/a

MGX 소개

Metagenomi Therapeutics, Inc. an in vivo genome editing company, develops curative genetic medicines in the United States. The company's lead development program, MGX-001, is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia. It has a collaboration agreement with Ionis Pharmaceuticals, Inc. for apolipoprotein C-III for the treatment of hyper triglyceridemia, transthyret...

[더 보기]
산업 Biotechnology
섹터 Healthcare
IPO 일자 Feb 9, 2024
직원 수 113
상장 거래소 NasdaqGS
티커 MGX
웹사이트 https://metagenomi.co
전체 기업 정보

재무 실적

2025년 Metagenomi Therapeutics의 매출은 25.21M로, 전년 52.3M 대비 -51.79% 감소했습니다. 순이익은 -87.87M로, 12.57% 증가했습니다.

재무제표

어닝 서프라이즈

Metagenomi Therapeutics가 Aug 10, 2026에 분기 실적을 발표했습니다:
  • 매출 $1.25M 예상치 하회 $0, 및 -69.76% 전년 대비 감소.
  • EPS -0.73 예상치 하회 -0.21, 및 -35.19% 전년 대비 감소.

    • 다음 실적 발표

    Metagenomi Therapeutics Inc.의 실적 발표 예정일은 Aug 13, 2025, 장 마감 후입니다.
    애널리스트 예상 매출은 ... 업그레이드
    news image

    1주 전 · Zacks

    Metagenomi Therapeutics (MGX) Reports Q2 Loss, Lags Revenue Estimates

    Metagenomi Therapeutics (MGX) delivered earnings and revenue surprises of -15.87% and -120.56%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stoc...

    news image

    1주 전 · Zacks

    Amphastar Pharmaceuticals (AMPH) Q2 Earnings and Revenues Top Estimates

    Amphastar (AMPH) delivered earnings and revenue surprises of +37.88% and +1.08%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

    news image

    2주 전 · Zacks

    Personalis (PSNL) Reports Q2 Loss, Tops Revenue Estimates

    Personalis (PSNL) delivered earnings and revenue surprises of -20.00% and +30.21%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

    news image

    3개월 전 · Simply Wall St.

    Metagenomi Therapeutics, Inc. (NASDAQ:MGX) Just Reported And Analysts Have Been Cutting Their Estimates

    Metagenomi Therapeutics, Inc. ( NASDAQ:MGX ) missed earnings with its latest first-quarter results, disappointing...

    news image

    3개월 전 · Zacks

    Metagenomi Therapeutics (MGX) Reports Q1 Loss, Misses Revenue Estimates

    Metagenomi Therapeutics (MGX) delivered earnings and revenue surprises of -2.52% and -68.08%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock...

    2 페이지 중 1